Shortage of Hydromorphone Hydrochloride Injection
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA reports a current shortage of Hydromorphone Hydrochloride Injection, affecting various presentations, with some available and others limited or unavailable as of April 2026.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Hydromorphone Hydrochloride Injection.
What's in Shortage
The generic drug Hydromorphone Hydrochloride Injection, with brand names including HYDROMORPHONE HYDROCHLORIDE and DILAUDID, is currently in shortage. It is available in injection dosage form and falls under the therapeutic category of Analgesia/Addiction. The shortage was first posted on November 1, 2017, and last updated on April 1, 2026.
Which Manufacturers Are Affected
Several manufacturers are impacted:
- Teva Pharmaceuticals USA, Inc.: Some presentations have limited availability, while others are available. Contact: 800-545-8800.
- Hospira, Inc., a Pfizer Company: Various presentations are available, limited, or unavailable due to manufacturing delays, with estimated recoveries in 2026. Contact: 844-646-4398.
- Fresenius Kabi USA, LLC: Some presentations are available, while others are unavailable with next releases in 2026. Contact: 888-386-1300.
Why There's a Shortage
The reason for the shortage is listed as 'Other' according to the FDA.
What Patients Should Do
If this shortage affects you, consider talking to your pharmacist or healthcare provider about the current availability. They can guide you on checking for supplies or other options. You may also contact the manufacturers directly for updates. Please remember to consult your healthcare provider for any medication-related decisions, as we do not provide medical advice.
Source
This information is sourced from the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,470 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.